Guardian of the Genome & Myc, page-5

There could be another explanation. Professor Sir David Lane may be interested in the FPP platform for intracellular delivery of cargo payloads.

We need to go back the March 2015 presentation and slide 27 titled MDM/p53 as a drug target in Cancer. Phylogica discusses a DPMI-∝ peptide that binds MDM2 with high affinity but can't penetrate cells. A FPP-DPMI-∝ enhances the delivery of the peptide into breast cancer cells. SoT covered it in his post of 2 March 2015, "so it’s possible [FPP] 1746 could be linked to not only omomyc, but to other protein drug molecules [such as DPMI-∝] that to-date have been unable to efficiently access inner cellular targets".

But what is the relationship of MDM2 to p53 and how does MDM2 imperil the Guardian of the Genome? Transcription factor p53 is a tumor suppressor that maintains normal cell processes. MDM2 tightly regulates p53. Abnormal activity by MDM2 can trigger p53 dysfunction leading to the replication of cancer cells.

In short, MDM2 drives p53 dysfunction in many cancers. The MDM-p53 pathway is one of the most highly targeted pathways in cancer drug development.

The nature of the collaboration with Lane remains unknown but a high probability exists that it involves p53. It could be a FPP-payload cargo targeting MDM2 or it could be the dual targeting of the MDM2-p53 and Myc pathways vis-a-vis the work with Doug Fairlie and the Bcl-2 and Myc pathways!!!

Could we find out at The 17th International p53 workshop to be held in Singapore in July 2017? The workshop is now listed in Phylogica's events calendar.